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The HIV risk-taking behavior scale (HRBS) is an 11-item instrument designed to assess
the risks of HIV infection due to self-reported injection-drug use and sexual behavior. A
retrospective analysis was performed on HRBS data collected from approximately 1,000
participants pooled across seven clinical trials of pharmacotherapies for either the treat-
ment of cocaine dependence or methamphetamine dependence. Analysis faced three
important challenges. The sample contained a high proportion of missing assessments
after randomization. Also, the HRBS scale consists of two distinct behavioral components
which may or may not coincide in response patterns. In addition, distributions of responses
on the subscales were highly concentrated at just a few values (e.g., 0, 6).To address these
challenges, a single probit regression model was ﬁt to three outcomes variables simulta-
neously – the two subscale totals plus an indicator variable for assessments not obtained
(non-response).This joint-outcome regression model was able to identify that those who
left assessment early had higher self-reported risk of injection-drug use and lower self-
reported risky sexual behavior because the model was able to draw on information on
associations among the three outcomes collectively. These ﬁndings were not identiﬁed
in analyses performed on each outcome separately. No evidence for an effect of pharma-
cotherapies was observed, except to reduce missing assessments. Univariate-outcome
modeling is not recommended for the HRBS.
Keywords: cocaine dependence, latent variables, methamphetamine dependence, missing assessment, multivari-
ate outcome, probit regression
INTRODUCTION
Injection-drug users are not only susceptible to HIV infection
throughinjection,especiallygivenHIV’sextendedviabilitywithin
syringes(Abdalaetal.,1999),butalsothroughunprotectedsexual
contact with those infected with HIV, including other injection-
drug users (Strathdee and Stockman, 2010). A recent estimate of
the quantity of HIV infected injection-drug users worldwide is
0.8–6.6 million (Mathers et al., 2008).
The HIV risk-taking behavior scale (HRBS) is an 11-item
instrument designed to assess “the behavior of intravenous drug
users in relation to both injecting and sexual behavior” (Darke
et al., 1991). Six items assess injection-drug use and ﬁve items
assess sexual behavior. Darke et al. (1991) reported an estimated
internal reliability of α≈0.70, test–retest reliability of r ≈0.86,
and item-level percentage agreement with surrogates exceeding
81%. Petry (2001) reported similar estimates of reliability in a
separate study.
TheDivisionofPharmacotherapiesandMedicalConsequences
of Drug Abuse at the National Institute on Drug Abuse has
employed the HRBS in various clinical trials for the treatment of
cocaine or methamphetamine dependence (e.g., Anderson et al.,
2009; Kahn et al., 2009). In conducting the current study, gener-
alized estimating equations (GEE) were considered and applied
in early analyses, as this had been done with other outcomes in
prior work by the Division; however, these initial analyses made
evidentthatHRBSdatacollectedfromthesestudiesposethreesig-
niﬁcant challenges that marginal-modeling such as GEE appeared
ill-equipped to address. (1) Roughly one-quarter to one-half of
those providing baseline assessments did not provide assessments
post-randomization; and the possibility existed that assessments
were missing in an informative way. (2) The HRBS consists of two
distinct domains (injection-drug use and sexual behavior),which
may not coincide in their response to interventions designed to
reduce substance dependence. (3) These subscale totals tend to
be highly concentrated at one or two particular values creating
sharply peaked and/or bimodal distributions, even though each
subscalespansarangeof possibletotals(30forinjection-drug-use
subscale and 25 for sexual-behavior subscale).
The purpose of this paper is to address the analytic challenges
of the HRBS simultaneously in a single, comprehensive regres-
sionmodelingframeworkandtherebyprovideinvestigatorswitha
toolkitforevaluatinglongitudinalHRBSassessments.Themethod
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isdescribedandjustiﬁedinsomedetailandresultsareinterpreted
carefullyintermsofqualityofmodelﬁt.Thepaperconcludeswith
discussion of implications for research in HIV risk behaviors.
METHODS
The ﬁrst of the three analytic issues to address was missing assess-
mentsafterrandomization.Whetherornotaparticipantprovides
anassessment(i.e.,non-response)maybejustasmuchanoutcome
to an intervention as is the clinical outcome of interest itself (e.g.,
injection-drug-use subscale total). Statistical methods have been
developed to model non-response and clinical outcomes together.
Rather than ﬁt one regression model for non-response and a sep-
arate regression model for clinical outcome, a single regression
model is ﬁt using both types of outcome variables simultaneously
– i.e., “joint modeling.” Properly speciﬁed, joint modeling may
reduce bias when one of the response variables is non-response
and responsiveness is “informative” in the sense that participants
are failing to provide assessments for reasons related to their clin-
ical outcomes (see references in Guo and Carlin, 2004). Joint
modeling also permits both subscale totals to be modeled simul-
taneously, providing insights into the multivariate nature of HIV
behaviors. As a bonus, joint modeling can also improve statistical
power through increasing the stability (efﬁciency) of regression
coefﬁcientestimates,becauseeachoutcomecanleverageinforma-
tion from the other. This property has been recognized for some
time and, for example, is the motivation behind the method of
seemingly unrelated regressions (Pindyck and Rubinfeld, 1981).
The third analytic issue concerns the strongly peaked and/or
bimodal distributions of the subscale totals. This was addressed
in the present study by re-coding each scale and use of probit
regression. Due to the very high proportions of zeroes for the
injection-drug-use subscale total (see Results), this outcome was
transformedtoabinaryscaleof0,foratotalof0,and1,foranytotal
greater than zero. Because totals of 0 and 6 accounted for ∼30%
and ∼22%, respectively, of all responses on the sexual-behavior
subscale, transformation was to an ordinal scale as follows.
Original New
00
1t o5 1
62
7≤ 3
Non-response was coded as 1 for each visit on which an HRBS
assessment was not obtained (both subscale totals missing) and 0
otherwise. Trivariate probit regression permitted joint modeling
of non-response and both of the two HRBS outcomes (subscale
totals) using these binary and ordinal scales. Initially, separate
bivariateprobitmodelswereﬁttothesedata,oneforeachsubscale
outcome and the missing assessment outcome; but it was recog-
nized that potentially valuable information about the relationship
between subscales was being ignored. The trivariate probit model
assumed that each true outcome was an unobserved (latent) con-
tinuous variable; and that the outcome observed was an ordered
partitioning of the unobserved scale. One can think of the three
latent outcomes in this study as continuous measures of the ten-
dencyto(1)engageinriskyinjection-druguse,(2)engageinrisky
sexual behavior, and (3) not provide HRBS assessments (non-
response). Analogously to Kim (1995), we allowed underlying
latent variables to be correlated.
We modeled this correlation using a shared random effect
(Hedeker and Gibbons, 2006). After controlling for other fac-
tors, a shared random-effect represents the combined effects of
one to many latent factors that are associated with deviations of
individuals’HIV risk behaviors and non-response from the group
mean. Here“group”is all individuals with the same set of baseline
traits (including randomization assignment). To facilitate estima-
tion (i.e., “identiﬁcation”), the shared random-effect regression
coefﬁcient was set to 1 for non-response, to serve as the reference
outcome; the shared random-effect’s mean was set to zero and its
variance was set to 1.
Data were pooled from seven randomized,placebo-controlled,
double-blind clinical trials (modaﬁnil–cocaine, tiagabine–
cocaine, reserpine–cocaine, ondansetron–cocaine, baclofen–
cocaine, bupropion–methamphetamine, and ondansetron–
methamphetamine). The regression model contained the follow-
ing baseline regressors that were captured under each of these
protocols: self-reported use of target substance of dependence
during the 30-days prior to baseline, age (years), race, and gen-
der. An additional regressor was included for the type of therapy
(individualorgroup)providedtobothstudyarmsthroughoutthe
active-interventionperiodperthetrial’sprotocol.Inearlyanalyses,
selection models were ﬁt separately by trial.We realized that pool-
ing trials would be more efﬁcient. The regressors of use 30days
prior to baseline,age,race,and gender were included to adjust for
possible population differences across trials. Categorical regres-
sors were coded as 0/1 binary indicator variables. Race variables
were created for African-American and white via two binary vari-
ables so that each represents comparison to other racial groups
(i.e., neither White nor African-American). No distinction was
made between multiple active doses within a trial (e.g., 200 and
400mgof modaﬁnil)incodingtheregressorforplacebovs.active.
Intercept terms were excluded from these trivariate probit models
to facilitate identiﬁcation on latent scales (Mahabadi and Ganjali,
2010).
Trials varied in the quantity of scheduled assessments at
which the HRBS was to be captured (one baseline plus one
or two post-randomization assessments) and in length of the
active-intervention period (8 or 12weeks). All trials had one
post-randomization assessment scheduled at the end of the
active-intervention period and some had a subsequent post-
randomization assessment at end of ensuing follow-up. The
trivariateprobitmodelemployedasetof regressorsfortime.Time
was coded as days elapsed since randomization so that baseline
assessments had negative time values and all post-randomization
assessments had positive time values. Use of a continuous piece-
wise linear spline allowed the slope to be zero prior to random-
ization, to possibly become non-zero after randomization, and
then possibly change in value again from the end of the active-
intervention period through follow-up. First-order interactions
between time and study arm (placebo or active) allowed slopes
to differ between these two groups during the active-intervention
period and during follow-up. No main effect for study arm was
includedbecausethiswouldestimatethedifferencebetweenstudy
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arms at randomization, which randomization should have forced
to zero. Time effects were not included for the non-response
outcome for two reasons. The ﬁrst was that a follow-up period
assessment was only provided by protocol for two of the seven
trials; so, for the majority of trials, a non-response outcome was
only possible at one assessment after randomization. The second
reason is that the timing of an assessment was not recorded if
no assessment was made, creating a missing value for time where
non-response occurred. Non-response was coded as missing (and
thereby treated as non-informative) for the third assessment of
those ﬁve trials where the protocol only required assessments at
baseline and end of active-intervention period.
To facilitate ﬁtting-algorithm convergence, the regressors were
mean-centeredandscaledtounitSD.Fortimeanditssplineterm,
centering and scaling followed Gram–Schmidt orthogonalization
toeliminateanycollinearitythatcouldinﬂateSEandreducestatis-
tical power. Attained signiﬁcance levels of p <0.05 were declared
statistically signiﬁcant. All analyses were performed in SAS® v. 9.2
(SAS Institute, Cary, NC, USA).
All trials in the pooled sample were reviewed and approved
by Institutional Review Boards, at the participating sites, and by
a central Data and Safety Monitoring Board. Informed consent
was obtained from all participants. This manuscript was inter-
nallyapprovedbytheDivisionof PharmacotherapiesandMedical
Consequences of Drug Abuse (NIDA).
RESULTS
Three observations were dropped as part of data quality control
because they occurred either more than 1year prior or 1year after
the date of randomization and almost certainly represented gross
date coding errors.An additional observation was dropped due to
amissingvalueonabaselineregressor.Thisleftatotalsamplesize
of 999 participants.
Table 1 provides the baseline characteristics of the participants
in the pooled sample. Participants self-reported using the drug of
dependenceforabout15outof the30-dayspriortobaseline.Aver-
age age was ∼40years. African-Americans and Whites together
constituted roughly 75% of the sample. 58% of participants were
randomly assigned to an active study arm.
Table 2 demonstratesthattheobservedsamplemeansdeclined
across the three successive assessments. Sample size also declined
post-randomization. By the end of the active-intervention period,
only71%ofbaselinerespondentsprovidedassessments(n =705).
Samplesizedroppedsubstantiallybythethirdassessmentbecause
only two of the seven trials (modaﬁnil–cocaine and tiagabine–
cocaine) required a third assessment by protocol.
Table 3 summarizes regression ﬁndings for joint modeling of
non-response, drug-use subscale total, and sexual-behavior sub-
scale total. Risky sexual behavior and non-response may both
decline with increasing age (p ≤0.0004). Risky sexual behavior
(p =0.0039) and non-response (p <0.0001) may also both be
associated with individual therapy, although association appears
to be in opposite directions per their regression coefﬁcient esti-
mates. How to interpret this ﬁnding is not clear since only cocaine
trials employed individual therapy and only methamphetamine
trials employed group therapy. Table 3 also indicates that whites
may demonstrate signiﬁcantly more risky injection-drug use than
Table 1 | Baseline characteristics of pooled sample.
Baseline characteristic Mean SE
Use last 30days 14.92 0.32
Age (years) 39.71 0.28
Individual therapy 0.69 0.01
White 0.39 0.02
African-American 0.37 0.02
Female 0.29 0.01
Active 0.58 0.02
Variables in last ﬁve rows were coded as 1=present and 0=absent, so these
means are proportions (e.g., 58% of participants were randomly assigned to an
active study arm on average). Sample size is 999 throughout.
Table 2 | Summary of outcomes by assessment: 1=baseline, 2=end
of active-intervention period, and 3=end of follow-up.
Assessment Injection-drug-use
subscale total
Sexual-behavior
subscale total
Mean SE N Mean SE N
1 0.69 0.08 993 4.46 0.13 993
2 0.30 0.06 704 3.88 0.15 705
3 0.08 0.06 209 3.65 0.27 209
Six participants did not provide baseline assessments. One participant provided a
total on the sexual-behavior subscale but not on the injection-drug-use subscale.
Results do not include three participants from baclofen–cocaine and bupropion–
methamphetamine who returned for a third assessment, as these observations
would have been obtained contrary to those trials’ protocols and may represent
coding errors.
other racial groups (p =0.0283); and non-response was lower in
active arms (p =0.0200).
The coefﬁcient estimate of the shared random effect for the
injection-drug-use subscale total was positive and statistically sig-
niﬁcant(3.05,p <0.0001),whichcontrastswiththenegativecoef-
ﬁcientforthesexual-behaviorsubscaletotal(−0.598,p <0.0001).
Together, the signs of the three shared random-effect coefﬁcients
indicate that one or more latent factors couple an increased ten-
dency for non-response (+ coefﬁcient) with an increased ten-
dency for risky injection-drug use (+ coefﬁcient) and a reduced
tendency for risky sexual behavior (− coefﬁcient). Assessments
appear to be missing in an informative way. In practical terms,
after accounting for the other factors in the model, those who
choose not to provide assessments may also be doing worse in
terms of injection-drug-use risk-taking and better in terms of
sexual-behavior risk-taking.
These ﬁndings are consistent with detected trends in means
over time. After adjusting for non-response, self-reported risky
injection-drug-use appears to increase over time between base-
lineandendof theactive-interventionperiod(p =0.0011).Those
who are leaving assessment have elevated risky injection-drug
use and that is causing injection-drug risk-taking to increase on
average within the population over time. Due to the formula-
tion of the regression model, this time trend is, strictly speaking,
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Table 3 | Fit of trivariate probit regression model simultaneously to the three outcome variables of (1) dichotomized injection-drug-use
subscale total, (2) four-category ordinal scale for sexual-behavior subscale total, and (3) non-response. Coefﬁcient estimates are on scale of latent
(unobserved) variables.
Outcome variable Explanatory variable Coefﬁcient estimate SE p-value
Injection-drug-use subscale total Use last 30days 0.05952 0.1269 0.6392
Age (years) 0.02486 0.1254 0.8429
Individual therapy −0.1329 0.1382 0.3364
White 0.3385 0.1541 0.0283
African-American 0.05124 0.1766 0.7718
Female −0.03584 0.1215 0.7681
Days 0.2208 0.06718 0.0011
Follow-up days (8) −0.02579 0.2083 0.9015
Follow-up days (12) −0.08676 0.07961 0.2760
Days×active −0.09659 0.06685 0.1488
Follow-up days×active (8) −0.1008 0.2156 0.6404
Follow-up days×active (12) −0.02089 0.07949 0.7928
Shared random effect 3.0516 0.2656 <0.0001
Sexual-behavior subscale total Use last 30days −0.00006 0.03384 0.9985
Age (years) −0.1183 0.03356 0.0004
Individual therapy −0.1086 0.03751 0.0039
White 0.002274 0.04083 0.9556
African-American 0.06427 0.04653 0.1675
Female 0.04399 0.03190 0.1683
Days −0.1542 0.02683 <0.0001
Follow-up days (8) −0.01499 0.08431 0.8589
Follow-up days (12) 0.009267 0.03043 0.7608
Days×active 0.03357 0.02635 0.2029
Follow-up days×active (8) 0.02448 0.08876 0.7828
Follow-up days×active (12) −0.02892 0.03056 0.3443
Shared random effect −0.5980 0.04111 <0.0001
Non-response Use last 30days −0.00088 0.05544 0.9874
Age (years) −0.2233 0.05523 <0.0001
Individual therapy 0.2975 0.06311 <0.0001
White 0.03650 0.06809 0.5920
African-American −0.00269 0.07521 0.9715
Female −0.04622 0.05249 0.3788
Active −0.1006 0.04317 0.0200
Shared random effect 1 – –
Model terms are detailed in Methods. “Days×active” is difference in slopes over time for active minus placebo during the active-intervention period. “Follow-up
Days×Active” is difference in the change in slopes from end of active-intervention period through follow-up for active minus placebo. Values in parentheses (8 or
12) refer to slope being allowed to differ over follow-up period depending upon length of active-intervention period. “Shared random-effect coefﬁcient” is regression
coefﬁcient for shared random effect of that outcome.This coefﬁcient was set to one for non-response outcome.
only for those on placebo. However, no differences in slopes
were detected between active and placebo during active inter-
vention or follow-up for the injection-drug-use subscale total
(p ≥0.1488). In contrast, because non-response was associated
with lower sexual-behavior subscale totals, outcome on this sub-
scaleisestimatedtodeclineonaverageovertheactive-intervention
period (p <0.0001). That is, the population self reports less risky
sexual-behavior over time. For this subscale total, no evidence is
observed for a difference in slopes between active and placebo
during active intervention or follow-up (p ≥0.2029).
Thepotentialadvantageshereof jointmodelingarebiasreduc-
tion through correction for informatively missing assessments,
increased statistical power, and additional insights into the rela-
tionship between the two HRBS subscales. For comparison,
univariate probit regression models were ﬁt, with a model for
injection-drug-use subscale total as an outcome and a sepa-
rate model for sexual-behavior subscale total as an outcome.
Like the trivariate-outcome model, univariate-outcome analyses
foundthatwhitesdemonstratemoreriskyinjection-drugusethan
other racial groups (regression coefﬁcient=0.367, p =0.0139);
and risky sexual-behavior declines with age (regression coefﬁ-
cient=−0.174,p =0.0006)andisnegativelyassociatedwithindi-
vidual therapy (regression coefﬁcient=−0.152,p =0.0066). Fur-
ther, as with the trivariate-outcome model, univariate-outcome
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modelingfoundadeclineinriskysexual-behaviorovertheactive-
interventionperiod(regressioncoefﬁcient=−0.142,p <0.0001).
No other effects were detected for the univariate-outcome mod-
els (data not shown), which contrasts to the trivariate-outcome
model’s ﬁnding that risky injection-drug-use increases during
active intervention (Table 3). Presumably this difference arose
because trivariate-outcome modeling allowed the ﬁt for each out-
come to leverage information from the others via the shared ran-
dom effect. Univariate-outcome modeling is not recommended
for the HRBS.
Does evidence of positive association exist between non-
response and risky injection-drug use in the observed data? Obvi-
ously, observed data cannot provide a complete answer because
the unobserved responses were unobserved and probit model-
ing is on the outcomes’ underlying latent scales. Even so, a rough
approximation is available from the observed data. Table 4 pro-
vides the sample mean for each HRBS subscale total at baseline
as stratiﬁed by non-response status at the end of the active-
intervention period. Compared to respondents,non-respondents’
baseline mean was approximately 13% higher on the injection-
drug-use subscale total,which is in the same direction as detected
by the trivariate-outcome model. In contrast, on the sexual-
behavior subscale total, non-respondents’ baseline mean was 5%
higher than respondents’, which is opposite in direction from
that detected by the trivariate-outcome model but also nearly
threefold smaller than the difference between respondents’ and
non-respondents’meansfortheinjection-drug-usesubscaletotal.
Also, the signs of the subscales’ coefﬁcients for the shared
random effect were opposite, indicating negative association
(Table 3). The observed data also contains evidence for a negative
association between these two HRBS components. Table 5 reveals
that the only detectable association between these two subscale
totals was negative in sign (ˆ τ=−0.0729, p =0.0255).
Alookatthedistributionoftheestimatedsharedrandomeffect
does provide some additional insights into its latent structure
(Figure 1). Per standard approach, the regression model assumed
that the shared random effect has a normal distribution of mean
zero.Clearly,neitherof thoseassumptionsaremet.Thehistogram
and a non-parametric density estimator reveal a distribution that
is bimodal with the larger of the two modes below zero. Inter-
estingly, the smaller mode is approximately located at zero. The
reasonforthisdeparturemaybethat,whilerandomeffectsaretyp-
ically used to estimate the collective impact of many small latent
factors, in this population perhaps included among those smaller
effects is a dominant larger latent effect. In particular,this appears
to be a grouping variable, which would explain the presence of
two distinct modes with one at zero. The implication is that the
Table 4 | Estimated sample mean (SE) of HRBS subscale totals at
baseline stratiﬁed by non-response status at the end of the
active-intervention period.
End of active-intervention period
Respondents Non-respondents
Injection-drug use (baseline) 0.67 (0.10) 0.76 (0.15)
Sexual behavior (baseline) 4.39 (0.15) 4.62 (0.25)
Table 5 | Association between HRBS subscale totals for assessments
1=baseline, 2=end of active-intervention period, and 3=end of
follow-up.
Sexual
behavior 1
Sexual
behavior 2
Sexual
behavior 3
Injection-drug use 1 ˆ τ = 0.0098 ˆ τ =− 0.0729 ˆ τ =− 0.0480
p =0.7181 p =0.0255 p =0.4322
Injection-drug use 2 ˆ τ = 0.0415 ˆ τ =− 0.0237 ˆ τ = 0.0110
p =0.2024 p =0.4691 p =0.8620
Injection-drug use 3 ˆ τ = 0.0544 ˆ τ = 0.0508 ˆ τ = 0.0641
p =0.3703 p =0.4197 p =0.2972
Association is measured as concordance via estimates ˆ τ of Kendall’s τ.
FIGURE1|F r equency histogram of predicted shared random effect
from the ﬁtted trivariate probit regression model. Overlain on the
histogram are a ﬁtted normal distribution (solid line) and a non-parametric
kernel density estimate (dashed line) of the distribution.
regression model could be more correctly speciﬁed if the iden-
tity of this large, latent grouping factor were known. A clue to its
identity is suggested by the fact that the shared random effect has
a particularly strong association with the non-response outcome
(r =0.59,p <0.0001)butmoremodestassociationswiththeHIV
risk-taking subscale totals at baseline (|r|≤0.42,p <0.0001).
DISCUSSION
Because the regression model incorporated associations among
all three outcomes, analysis was able to identify that those who
leave assessment may have more risky injection-drug use and
less risky sexual-behavior subscale scores. Exactly why a nega-
tive association between these two HRBS components may exist
is an open question and worthy of further investigation for the
design of interventions to help reduce HIV risk-taking behaviors.
Withdrawal-induced relapse and binging (Gawin and Ellinwood,
1988) may partly explain why those who leave substance-
dependencetreatmentearlyhaveincreasedrisk-takingwithregard
to injection-drug use. Self-reported risky sexual behaviors may
have been more amenable to counseling and thereby declined
becausethesebehaviorswereadjuncttotheprimarydisorder(sub-
stancedependence)withintherecruitmentpopulation.Thatrisky
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sexual behaviors may have declined could be an important ﬁnd-
ing especially since reducing this risk has proven difﬁcult among
stimulant abusers (Metzger et al., 2010).
Analysis did not detect any evidence that HRBS response dif-
fersbetweenactiveandplaceboconditionsdespitethelargesizeof
this retrospective sample and adjustment for non-response. Uni-
variate analyses reached the same conclusion (data not shown).
This ﬁnding may not be surprising given that the active treat-
ment conditions were targeted to reduce degree of depen-
dence on cocaine or methamphetamine and not speciﬁcally to
reduce HIV risk-taking behaviors. Even though none of the
published analyses of the clinical trials within the pooled data
set demonstrated improvement on their respective primary out-
comes of drug dependence, perhaps the ﬁnding reported here
that active condition reduced non-response (Table 3; p =0.0200)
suggests that some active medications can improve patient
participation, which could be one component of an effective
intervention for substance dependence and risky injection-drug
behaviors. From a statistical perspective, though correlated, non-
response, and outcome on HRBS subscales appear to be distin-
guishable processes, with non-response separably governed by
at least one distinct factor, the active condition. This “exclu-
sion restriction” may have been responsible for this study’s
detection of selection bias in the HRBS subscales (Puhani,
2000).
Early analyses employed GEE; but GEE was abandoned due to
its limitations. For example, GEE assumes that data are missing
completely at random (Little and Rubin, 2002), which the above
analysessuggestisincorrectforthispopulation.Themissingcom-
pletely at random assumption can be relaxed slightly using a
multiple-imputation version of GEE (MI-GEE; Beunckens et al.,
2008); however, even MI-GEE does not allow for the possibil-
ity that assessments can be missing informatively (Beunckens
et al., 2008). The MI-GEE approach also adds the complica-
tion of requiring development of an imputation model (Schafer,
1997). For the current study, initially a different univariate mixed
modeling approach was tried that assumed a mixture distri-
bution of the sexual-behavior subscale total, allowing for its
observed bimodal structure. That complicated estimation sub-
stantially through reliance on an expectation–maximization algo-
rithm (Little and Rubin, 2002); and that added computational
complexitycamewithoutthebeneﬁtsofthemultivariate-outcome
analysis,as detailed above. Shared-parameter models were also ﬁt
that employed a bivariate outcome: (1) the last value observed
on each subscale outcome for each person and (2) the timing of
that last outcome. These models suffered from ﬁtting-algorithm
convergence problems, probably because they only utilized one
observation per person.
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